LAG3 and melanoma: LSECtin, a cell surface lectin of the DC-SIGN family, has been identified as an alternative ligand for LAG-3, and LAG-3 blockade has been shown to result in abrogation of immunoinhibitory effects of LSECtin in a melanoma mouse model (34).